|
|
|
|
| LEADER |
03636nmm a2200289 u 4500 |
| 001 |
EB000613638 |
| 003 |
EBX01000000000000000466720 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9780306468476
|
| 100 |
1 |
|
|a Lajtha, Abel
|e [editor]
|
| 245 |
0 |
0 |
|a Role of Proteases in the Pathophysiology of Neurodegenerative Diseases
|h Elektronische Ressource
|c edited by Abel Lajtha, Naren L. Banik
|
| 250 |
|
|
|a 1st ed. 2002
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 2002, 2002
|
| 300 |
|
|
|a XIV, 302 p
|b online resource
|
| 505 |
0 |
|
|a The Role of Proteolytic Eenzymes in Autoimmune Demyelinating Diseases: An Update -- Proteases in Demyelination -- Calcium Activated Neutral Proteinase in Demyelinating Diseases -- Papain-like Cysteine Proteases and Their Implications in Neurodegenerative Diseases -- The Role of the Calpain System in Neuromuscular Disease -- The Role of Calpain Proteolysis in Cerebral ischemia -- Calpain Isoforms in the Eye -- Metalloendopeptidase EC 3.4.24.15 in Neurodegeneration -- Cysteine Proteases, Synaptic Degeneration and Neuroodegenerative Disorders -- The Ubiquitin/Proteasome Pathway in Neurological Disorders -- Amyloid (Tace, Bace) and Presenilin Proteases Associated with Alzheimer’s Disease -- Caspases in Neurodegeneration -- Therapeutic Approaches with Protease Inhibitors in Neurodegenerative and Neurological Diseases -- Pathophysiology of Central Nervpis System Trauma: Proteolytic Mechanisms and Related Therapeutic Approaches -- Lysosomal Cysteine Proteases and Their Protein Inhibitor -- Proteases and Their Inhibitors in Gliomas -- Proteolysis of Mutant Gene Products are Key Mechanisms in Neurodegenerative Diseases -- Mammalian Proteinase Genes
|
| 653 |
|
|
|a Neurosciences
|
| 653 |
|
|
|a Neurosciences
|
| 653 |
|
|
|a Neurology
|
| 653 |
|
|
|a Neurology
|
| 700 |
1 |
|
|a Banik, Naren L.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/b111075?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 612.8
|
| 520 |
|
|
|a Researchers seeking problems that offer more hope of success often avoid subjects that seem to be difficult to approach experimentally, or subjects for which experimental results are difficult to interpret. The breakdown part of protein turnover in vivo, particularly in nervous tissue, was such a subject in the past – it was difficult to measure and difficult to explore the mechanisms involved. For factors that influence protein metabolism, it was thought that protein content, function, and distribution are controlled only by the synthetic mechanisms that can supply the needed specificity and response to stimuli. The role of breakdown was thought to be only a general metabolic digestion, elimination of excess polypeptides. We now know that the role of breakdown is much more complex: it has multiple functions, it is coupled to turnover, and it can affect protein composition, function, and synthesis. In addition to eliminating abnormal proteins, breakdown has many modulatory functions: it serves to activate and inactivate enzymes, modulate membrane function, alter receptor channel properties, affect transcription and cell cycle, form active peptides, and much more. The hydrolysis of peptide bonds often involves multiple steps, many enzymes, and cycles (such as ubiquination), and often requires the activity of enzyme complexes. Their activation, modification, and inactivation can thus play an important role in biological functions, with numerous families of proteases participating. The specific role of each remains to be elucidated
|